GLP1R and Obesity: In Saudi Arabia, gallstones remain the leading cause of AP, but the increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss, in the context of obesity rates exceeding 35%, may represent an emerging risk factor (Faillie et al., 2016; Alkhiari et al., 2021).